Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for ...

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Oxford BioTherapeutics inks multi-year collaboration with Roche to discover novel targets for antibody-based therapeutics to treat cancer: Oxford, UK Thursday, March 20, 2025, 17: ...

Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new targets for antibody-based cancer treatments ...